TY - JOUR
T1 - Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations
AU - Mattox, Austin K.
AU - Wang, Yuxuan
AU - Springer, Simeon
AU - Cohen, Joshua D.
AU - Yegnasubramanian, Srinivasan
AU - Nelson, William G.
AU - Kinzler, Kenneth W.
AU - Vogelstein, Bert
AU - Papadopoulos, Nickolas
N1 - Funding Information:
This work was supported by The Virginia and D.K. Ludwig Fund for Cancer Research, the Lustgarten Foundation for Pancreatic Cancer Research, and National Institutes of Health Grants P50-CA62924, CA 06973, and GM 07309.
PY - 2017/5/2
Y1 - 2017/5/2
N2 - The identification of mutations that are present at low frequencies in clinical samples is an essential component of precision medicine. The development of molecular barcoding for next-generation sequencing has greatly enhanced the sensitivity of detecting such mutations by massively parallel sequencing. However, further improvements in specificity would be useful for a variety of applications. We herein describe a technology (BiSeqS) that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA; its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. We show here that BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild-type molecules.
AB - The identification of mutations that are present at low frequencies in clinical samples is an essential component of precision medicine. The development of molecular barcoding for next-generation sequencing has greatly enhanced the sensitivity of detecting such mutations by massively parallel sequencing. However, further improvements in specificity would be useful for a variety of applications. We herein describe a technology (BiSeqS) that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA; its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. We show here that BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild-type molecules.
KW - Bisulfite sequencing
KW - Mutation
KW - Next-generation sequencing
KW - Polymerase chain reaction
KW - Strand-specificity
UR - http://www.scopus.com/inward/record.url?scp=85018727939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018727939&partnerID=8YFLogxK
U2 - 10.1073/pnas.1701382114
DO - 10.1073/pnas.1701382114
M3 - Article
C2 - 28416672
AN - SCOPUS:85018727939
SN - 0027-8424
VL - 114
SP - 4733
EP - 4738
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 18
ER -